![]() |
市场调查报告书
商品编码
1519761
2024-2032 年按产品、类型、应用、最终用途和地区分類的器官晶片市场报告Organ-on-chip Market Report by Offering, Type, Application, End Use, and Region 2024-2032 |
IMARC Group年,全球器官晶片市场规模达到6,160万美元。该市场的推动力是其在加强药物研发方面的关键作用,受到技术进步、协作努力以及透过医学研究中更准确和人性化的替代方案减少动物试验的监管和道德日益重视的刺激。
主要市场驱动因素:由于製药和生物技术领域对更准确和道德的研究方法的需求,晶片器官市场正在迅速扩张。
主要市场趋势:3D生物列印和微流体等技术进步正在彻底改变晶片器官模型,提高其准确性和适用性。
地理趋势:北美在强大的研究基础设施和积极的监管政策的支持下引领市场;然而,由于生物技术投资不断增加,欧洲和亚太地区正迅速迎头赶上。
竞争格局:器官晶片行业的一些主要市场参与者包括Allevi Inc.、Altis Biosystems、AxoSim、BiomimX Srl、Elveflow、Emulate Inc.、InSphero、MIMETAS、Nortis Inc.、TARA Biosystems Inc.、TissUse GmbH 等。
挑战与机会:虽然技术复杂性和高成本带来了挑战,但日益向个人化医疗的转变和向多器官模型的扩展带来了重要的器官晶片市场机会。
加强药物研发
器官晶片的市场潜力大大增加,因为它可以极大地促进药物的开发和发现。与传统的二维细胞培养物和动物模型相比,这些技术可以更精确地模拟人体器官的反应,因此有助于减少药物测试和开发的时间。因此,这项创新提供了无与伦比的预测准确性,对于减少药物发现过程中的持续时间、成本和失败率至关重要。因此,製药组织开始将器官晶片技术整合到其研发过程中,以缩小差距,从而推动个人化和精准医疗的进步以及更高的治疗成功率。此外,这种转变带来了许多药物快速获得批准的前景,这部分弥补了那些在最后阶段失败的药物的成本。
技术创新与合作
持续的技术进步是改变器官晶片产业的主要推动力之一。製造能够同时复製多个器官系统功能的晶片是一种更完整的分析工具,涵盖了临床前测试的第一阶段,并使临床试验更接近人群。正在进行的发明包括整合微流体、多维结构内的细胞 3D 列印以及自动化成像,使片上器官系统具有更好的功能和可扩展性。此外,生物技术公司、研究机构和技术专家之间的联合已经形成了跨学科研究的策略环境,从而促进了该领域的快速进步。这些合作对于克服技术问题和改进应用以及促进有毒物质检测、疾病建模和精准医学等各个领域至关重要。例如,器官晶片(OOC) 技术透过提供更准确的预测模型彻底改变了传统的体外 ADME 和毒性测试,从而促进药物开发,预计每年增长率为 15%。 OOC 平台结合了多器官系统,增强了药物动力学和药效学研究,提供了对药物分子的时间和剂量依赖性效应的深入了解。根据器官晶片市场收入,这些先进技术预计到 2025 年市场规模将达到 2.2 亿美元,其精确的流量控制和快速的样品处理优于传统的 2D 培养,使其对于功效研究和毒性评估至关重要。
监管与道德转变
关于动物在科学研究中的应用的伦理问题和更严格的法规也刺激了器官晶片产业的发展。世界各地的机构和部门逐渐认识到这些技术在提供比动物模型更相关的资料的价值。这正是美国食品药物管理局的器官晶片计画等项目所提倡的。因此,这种转变与公众和政府日益推动的动物友善调查技术是一致的。器官晶片技术不仅符合更高的监管标准,而且在伦理上也是有保证的,因为它们可以促进向更人性化和科学先进的研究技术的范式转移。这种道德立场在晶片器官设备用于研究和开发的更广泛批准中发挥着越来越重要的作用。
IMARC Group提供了每个细分市场的主要趋势分析,以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品、类型、应用和最终用途对市场进行了分类。
产品
服务
该报告根据发行提供了详细的市场细分和分析。这包括产品和服务。
肝
心
肺
肾
其他的
龙业占据产业最大份额
报告还提供了基于类型的详细市场细分和分析。这包括肝臟、心臟、肺、肾臟等。报告称,肺臟占了最大的市场份额。
根据器官晶片市场趋势,肺晶片由于其在呼吸系统研究和药物发现中的高应用而得到最广泛的应用。此技术适合对人体肺部的复杂结构和功能进行建模,为呼吸系统疾病、药物反应评估、吸入物质毒性评估提供动态平台。它在加速开发针对不同肺部疾病(例如气喘和慢性阻塞性肺病(COPD))的个人化疗法过程中的作用确实得到了强调。晶片肺模型可以更可靠、更合乎道德地取代动物试验,从而向当局保证药物的功效和安全性,这是成功进入市场的先决条件。这使得药物发现和生物技术成为该领域的领导角色,从而继续并增加器官晶片的市场份额。
生理模型开发
药物发现
毒理学研究
药物发现代表了领先的细分市场
该报告根据应用程式提供了详细的市场细分和分析。这包括生理模型开发、药物发现和毒理学研究。根据该报告,药物发现占据了最大的部分。
根据晶片器官市场概述,药物发现是药物开发所有阶段的最大部分。这是因为该部门拥有开发药品流程的关键转变方式。器官晶片系统可以以其他方式不可能的方式模拟人体器官在各种条件下的反应,使科学家能够对潜在药物进行早期筛选。电脑的这种能力成功地使我们能够估计这些药物将如何受到人体组织的影响,这反过来又朝着有效性和安全性测试过程的正确方向迈出了一步。因此,药物发现时间大大缩短,临床试验成本和风险也降低。製药公司对这些技术的广泛利用表明该领域存在一个巨大的机会,可以使药物搜寻更快,但不仅成本更低,而且符合更好的安全性和有效性监管要求。
製药和生物技术公司
学术及研究机构
化妆品产业
其他的
製药和生物技术公司在市场上表现出明显的主导地位
报告还提供了基于最终用途的详细市场细分和分析。这包括製药和生物技术公司、学术和研究机构、化妆品行业等。报告显示,製药和生物技术公司占据了最大的市场。
製药和生物技术公司占据最大的市场份额。这种优点主要是由于微器官模型在这些产业的药物发现和开发阶段的使用增加所致。器官晶片公司利用技术复製人体功能及其反应,其水平高于使用动物实验和二维细胞培养的传统方法。提高匹配人体器官功能和在实验室环境中相互作用的能力,可以在开发的早期阶段更好地检测药物功效和毒性。它不仅提高了临床试验成功的前景,而且减少了新药商业化过程中涉及的时间和成本。由于製药和生物技术公司不断寻找能够加速研发过程的创新方法,器官晶片技术的利用率预计将不断增加,因此使该细分市场成为市场上最大的细分市场,并创造了一个新的市场。器官晶片市场前景乐观。
北美洲
美国
加拿大
亚太
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
北美市场领先,占据最大的器官晶片市场份额
该报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告称,北美是器官晶片最大的区域市场。
根据晶片器官市场报告,最大的市场是北美。这种优势来自于强大的研究基础设施、生物技术和製药行业的良好资金支持,以及政府和私营部门对创新医疗保健解决方案的模范支持。地位随着器官晶片技术需求的不断增长,始终推动医学现场工作前沿的研究机构。除此之外,该领域还培育了一个现有的监管框架,为药物开发和个人化医疗(包括器官晶片)的尖端工具提供了很高的采用机会。这些经济实体的主导地位推动其他参与者进行创新,这些技术的开发和部署有助于在全球市场中占据区域主导地位。这种活跃且先进的兽医系统提供了器官晶片市场成长模型,使这些模型可用于医学研究和药物测试。
The global organ-on-chip market size reached US$ 61.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.8 Million by 2032, exhibiting a growth rate (CAGR) of 26.5% during 2024-2032. The market is driven by its critical role in enhancing pharmaceutical R&D, stimulated by technological advancements, collaborative efforts, and increasing regulatory and ethical emphasis on reducing animal testing through more accurate and humane alternatives in medical research.
Major Market Drivers: The organ-on-chip market is expanding rapidly, driven by the need for more accurate and ethical research methods in pharmaceuticals and biotechnology.
Key Market Trends: Technological advancements such as 3D bioprinting and microfluidics are revolutionizing organ-on-chip models, increasing their accuracy and applicability.
Geographical Trends: North America leads the market, supported by robust research infrastructure and proactive regulatory policies; however, Europe and Asia-Pacific are quickly catching up due to rising investments in biotech.
Competitive Landscape: Some of the major market players in the organ-on-chip industry include Allevi Inc., Altis Biosystems, AxoSim, BiomimX S.r.l., Elveflow, Emulate Inc., InSphero, MIMETAS, Nortis Inc., TARA Biosystems Inc., TissUse GmbH., etc. among many others.
Challenges and Opportunities: While technological complexities and high costs pose challenges, the growing shift towards personalized medicine and the expansion into multi-organ models present significant organ-on-chip market opportunities.
Pharmaceutical Research and Development Enhancement
The organ-on-chip market potential is greatly increased because it can dramatically enhance drug development and discovery. These techniques provide a more precise simulation of how human organs respond compared to conventional 2D cell cultures, and animal models and hence they help to reduce the time taken in drug testing and development. This innovation, thus, offers unparalleled prediction accuracy, essential for decreasing the duration, cost, and failure rates during drug discovery. As a result, pharmaceutical organizations are starting to integrate organ-on-chip technologies into their R&D processes to narrow the gap, leading to the advancement of personalized and precise medicine and higher therapeutic success rates. Besides, this shift produces the prospect of many quick drug approvals which partly cover the cost of those that failed in the final stage.
Technological Innovations and Collaborations
Continuous technological advancements are one of the major stimuli that are transforming the organ-on-chip industry. The manufacturing of chips capable of replicating several organ systems' functionalities at the same time is a more complete analysis tool, covering the first stage of preclinical testing and bringing clinical trials closer to the population. The inventions being made include incorporating microfluidics, 3D printing of cells within multi-dimensional structures, and automated imaging which allows for better functionality and scalability of organ-on-chip systems. Furthermore, associations between biotech firms, research institutions, and technology specialists have formed a strategic environment for cross-disciplinary studies that, in turn, results in fast improvements in this field. These collaborations are vital to overcoming technical issues and improving applications, as well as promoting various sectors like toxic things testing, disease modeling, and precision medicine. For instance, Organ-on-chip (OOC) technology revolutionizes traditional in vitro ADME and toxicity tests by offering a more accurate predictive model, enhancing drug development with an estimated growth rate of 15% annually. Incorporating multi-organ systems, OOC platforms enhance pharmacokinetic and pharmacodynamic studies, providing insights into the time and dose-dependent effects of drug molecules. Based on organ-on chip market revenue, these advanced technology, projected to reach a market size of $220 million by 2025, outperforms conventional 2D cultures with its precise flow control and rapid sample processing, making it essential for efficacy studies and toxicity evaluations.
Regulatory and Ethical Shifts
Ethical issues and stricter regulations concerning the application of animals in scientific research are additionally stimulating the growth of the organ-on-chip industry. Agencies and departments all around the world are coming to recognize the value of these technologies in providing more relevant data than animal models. This is what is being promoted by endeavors such as the USFDA's Organ-on-Chip program. Therefore, this transition is consistent with the growing public and governmental push for animal-friendly investigation techniques. Organ-on-chip technologies, not only qualifying for higher regulatory standards, are also ethically warranted, since they can promote a paradigm shift towards more human and scientifically advanced research techniques. This ethical standpoint is getting an increasing role in wider approval for organ-on-chip devices to be used in research and development.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on offering, type, application, and end use.
Products
Services
The report has provided a detailed breakup and analysis of the market based on the offering. This includes products and services.
Liver
Heart
Lung
Kidney
Others
Lung holds the largest share of the industry
A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes the liver, heart, lung, kidney, and others. According to the report, lung accounted for the largest market share.
According to the organ-on-chip market trend, the lung-on-chip is the most expanded due to its high application in respiratory studies and drug discovery. This technology is suitable for modeling the complex structure and function of the human lung to provide a dynamic platform for respiratory diseases, drug response evaluation, and inhaled substances toxicity assessment. Its role in the process of speeding up the development of personalized therapies for different lung diseases, such as asthma and chronic obstructive pulmonary disorder (COPD), is truly emphasized. Lung-on-chip model leads to a more reliable and ethical replacement of animal testing, hence the assurance of drug efficacy and safety to the authorities, which is a prerequisite for successful market entry. This shifts drug discovery and biotechnology to the leadership role in this area, continuing and increasing the organ-on-chip market share.
Physiological Model Development
Drug Discovery
Toxicology Research
Drug discovery represents the leading market segment
The report has provided a detailed breakup and analysis of the market based on the application. This includes physiological model development, drug discovery, and toxicology research. According to the report, drug discovery represented the largest segment.
As per the organ-on-chip market overview, drug discovery is the largest segment for all phases of drug development. This is because the segment has such a key transforming way of developing the processes of pharmaceutical products. Organ-on-chip systems can mimic human organs' responses under various conditions in a way that otherwise would be impossible, allowing scientists to do early screenings for a prospective drug. This ability of the computer successfully enables us to estimate how those drugs will be affected by the human tissues, which in turn creates a step in the right direction of the efficacy and safety test process. It therefore follows that the drug discovery time frame is greatly shortened, and the clinical trial costs and risk become lower. The broadening utilization of these technologies by a pharmaceutical company indicates a great opportunity in this area to make drug hunting faster but not only, less costly and in line with better regulatory requirements for safety and effectiveness.
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Cosmetics Industry
Others
Pharmaceutical and biotechnology companies exhibit a clear dominance in the market
A detailed breakup and analysis of the market based on the end use have also been provided in the report. This includes pharmaceutical and biotechnology companies, academic and research institutes, cosmetics industry, and others. According to the report, pharmaceutical and biotechnology companies accounted for the largest market share.
The pharmaceutical and biotechnology companies account for the largest market share. This superiority is mainly caused by the increased usage of micro-organ models in the drug discovery and development phases of these industries. The organ-on-chip companies use technology to copy human body functions and its responses to a higher level than conventional methods which use animal experimenting and 2D cell cultures. Improved capacities to match human organ functions and interact in a laboratory setting provide better detection of drug efficacy and toxicity at an early stage of development. It not only improves the prospects of success in the clinical trials but also decreases the time and cost involved in the process of commercialization of a new drug. Being that pharmaceutical and biotechnology company are constantly in search of inventive ways that will accelerate the research and development process, the utilization of organ-on-chip technologies is anticipated to keep increasing, therefore making this segment the largest one in the market and creating a positive organ-on-chip market outlook.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest organ-on-chip market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for organ-on-chip.
According to the organ-on-chip market report, the largest segment here is North America. This superiority comes from a strong research infrastructure, good funding of the biotechnology and pharmaceutical industry, and the exemplary support given to innovative healthcare solutions by the government and the private sector North American confident leadership in the market is further fortified by the existence of leading universities and research institutions that always drive the frontiers of the medical fieldwork with the Increasing organ-on-chip demand in technologies. Other than that, the area fosters an already existing regulatory framework that provides high adoption opportunities of cutting-edge tools for drug development and personalized medicine which include organ-on-chip. The dominance of these economic entities is what pushes other players to innovate the development and deployment of such technologies contribute to the regional prominence in the global market. This active and advanced veterinary system provides organ-on-chip market growth models which makes these models in use in medical research and pharmaceutical testing.
Allevi Inc.
Altis Biosystems
AxoSim
BiomimX S.r.l.
Elveflow
Emulate Inc.
InSphero
MIMETAS
Nortis Inc.
TARA Biosystems Inc.
TissUse GmbH
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Major players in the organ-on-chip industry keep improving and broadening their technological arsenals by different means, including research and development, cooperation, and mergers and acquisitions. According to organ-on-chip recent developments businesses aim to develop more specific and versatile organ-on-chip models capable of simulating human physiology more precisely for drug testing and disease modeling. The pragmatic cooperation is responsible for the quick product commercialization of new technologies in addition to broadening the microfluidic systems' application scope in personalized medicine, safety pharmacology, and complex biological research, which consequently fortifies their market positions. According to the organ-on-chip market forecast, strategic collaborations with pharmaceutical companies, academic institutions, and technology providers are creating a positive outlook for the market.
On March 7, 2023, Allevi, a pioneer in 3D bioprinting, adopted this transformative technology for its ability to accurately mimic human biological systems in animal-free research. Its expanding applications in drug discovery, regenerative and translational medicine, and preclinical research highlight the significant potential of this platform.
On January 23, 2024, CN Bio and Altis Biosystems partnered to create an advanced human Gut/Liver in vitro model for improved ADME studies, leveraging their organ-specific expertise for more accurate predictions. This next-generation Organ-on-a-Chip solution is available early through CN Bio's Contract Research Services.
On October 24, 2023, AxoSim, Inc., a leader in biomimetic human drug discovery platforms for neurological diseases, has completed its acquisition of microBrain(TM) assets from Vyant Bio's StemoniX subsidiary. This move enhances AxoSim's capabilities in advancing neurological research.